The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global Tenosynovial giant cell tumor treatment market grew at a CAGR of around 5% during 2015-2020. Tenosynovial giant cell tumor (TGCT) refers to neoplastic disorder that primarily affects the synovial lining of joints, tendon, and bursae, and cause them to thicken or overgrow. Some of the common symptoms include pain, swelling, stiffness, and reduced mobility in the affected limb or joints. Localized giant cell tumor and diffuse giant cell tumor are the two main types of TGCT. Localized giant cell tumors grow slowly and usually affect smaller joints, such as hands, whereas diffuse giant cell tumors readily multiply and affect larger joints, including hips, knees, ankles, shoulders, or elbows. TGCT treatment procedures widely include surgery, radiation therapy, and drug therapy.
The increasing prevalence of Tenosynovial giant cell tumor along with rising consumer awareness towards its early diagnosis and treatment is propelling the global market. Additionally, the wide availability of advanced surgical procedures for removing the tumor, radiation therapy, and pharmacotherapy, is further driving the market for TGCT treatment. Moreover, rising investments by several pharmaceutical companies in extensive R&D activities to introduce new targeted drugs for TGCT treatment are also catalyzing the global market. Furthermore, the introduction of numerous initiatives by various government and non-government organizations for creating awareness towards the early diagnosis and treatment of TGCT is further augmenting the market growth. In line with this, the increasing expenditures by several government bodies on the upgradations of healthcare facilities are also propelling the adoption of open surgery, arthroscopy, and total joint replacement surgeries for treating TGCT. In the coming years, several advancements in magnetic resonance imaging (MRI) technology for advanced imaging of the tumors, are further expected to drive the global market for TGCT treatment. Looking forward, IMARC Group expects the global Tenosynovial giant cell tumor market to continue its moderate growth during the next five years.
IMARC Group provides an analysis of the key trends in each sub-segment of the global Tenosynovial giant cell tumor treatment market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, disease type, treatment type and end-user.
Breakup by Disease Type:
Breakup by Treatment Type:
Breakup by End-User:
Breakup by Region:
The competitive landscape of the industry has also been examined with some of the key players being Daiichi Sankyo Company Limited, Deciphera Pharmaceuticals Inc., Five Prime Therapeutics Inc., and Novartis AG.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at